1. Home
  2. VKTX vs SKT Comparison

VKTX vs SKT Comparison

Compare VKTX & SKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VKTX
  • SKT
  • Stock Information
  • Founded
  • VKTX 2012
  • SKT 1981
  • Country
  • VKTX United States
  • SKT United States
  • Employees
  • VKTX N/A
  • SKT N/A
  • Industry
  • VKTX Biotechnology: Pharmaceutical Preparations
  • SKT Real Estate Investment Trusts
  • Sector
  • VKTX Health Care
  • SKT Real Estate
  • Exchange
  • VKTX Nasdaq
  • SKT Nasdaq
  • Market Cap
  • VKTX 3.8B
  • SKT 3.9B
  • IPO Year
  • VKTX 2015
  • SKT 1993
  • Fundamental
  • Price
  • VKTX $35.22
  • SKT $32.99
  • Analyst Decision
  • VKTX Strong Buy
  • SKT Buy
  • Analyst Count
  • VKTX 14
  • SKT 9
  • Target Price
  • VKTX $87.00
  • SKT $37.00
  • AVG Volume (30 Days)
  • VKTX 4.8M
  • SKT 813.2K
  • Earning Date
  • VKTX 10-22-2025
  • SKT 11-04-2025
  • Dividend Yield
  • VKTX N/A
  • SKT 3.52%
  • EPS Growth
  • VKTX N/A
  • SKT N/A
  • EPS
  • VKTX N/A
  • SKT 0.88
  • Revenue
  • VKTX N/A
  • SKT $561,024,000.00
  • Revenue This Year
  • VKTX N/A
  • SKT $2.56
  • Revenue Next Year
  • VKTX N/A
  • SKT $4.65
  • P/E Ratio
  • VKTX N/A
  • SKT $37.50
  • Revenue Growth
  • VKTX N/A
  • SKT 10.60
  • 52 Week Low
  • VKTX $18.92
  • SKT $28.69
  • 52 Week High
  • VKTX $79.10
  • SKT $37.57
  • Technical
  • Relative Strength Index (RSI)
  • VKTX 60.22
  • SKT 49.21
  • Support Level
  • VKTX $33.00
  • SKT $31.81
  • Resistance Level
  • VKTX $36.11
  • SKT $33.56
  • Average True Range (ATR)
  • VKTX 2.02
  • SKT 0.67
  • MACD
  • VKTX 0.09
  • SKT 0.06
  • Stochastic Oscillator
  • VKTX 73.40
  • SKT 62.77

About VKTX Viking Therapeutics Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

About SKT Tanger Inc.

Tanger Inc is an owners and operators of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers, with a total gross leasable area of approximately 13.0 million square feet.

Share on Social Networks: